What Is Biodexa Pharmaceuticals plc (BDRX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Biodexa Pharmaceuticals plc's intrinsic value is estimated at a composite fair value of $2.37. While the stock appears modestly undervalued at $2.24 (implied upside of +6.0%), our analysis suggests a thinner margin of safety across 3 of 5 bullish models. Notably, First Chicago sees the most upside at +106.1% (fair value: $4.62), while Sentiment SOTP is the most conservative at -90.6% ($0.21). The spread between these extremes — +196.7% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About BDRX?
5 of 13 models are currently active for BDRX. Of these, 3 models suggest upside while 2 models suggest overvaluation. The Bayesian DCF estimates BDRX's intrinsic value at $0.61, implying -72.7% downside from the current price. See which stocks rank higher →
How Does BDRX Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, BDRX ranks #411 by Quality of Company score. CirclFi's QOC score of 2.1/10 evaluates 32 fundamental signals. A score of 2.1 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Biodexa Pharmaceuticals plc's positioning within the Pharmaceutical Preparations segment means that R&D productivity ratio plays an outsized role in fundamental analysis. The sector's unique characteristics — including regulatory pathway clarity — shape both the opportunity set and risk profile.
Is BDRX a Value Trap?
The Value Trap algorithm is not active for BDRX. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
5 of 13 models are active for Biodexa Pharmaceuticals plc. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, Biodexa Pharmaceuticals plc earns a quality score of 2.1/10. This concerning rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +196.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every BDRX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across BDRX's 5 active models, average confidence is 2%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad